mTOR-targeted therapy of cancer with rapamycin derivatives (2005)
Vignot, S., Faivre, S., Aguirre, D., Raymond, E.
Rapamycin and its derivatives (CCI-779, RAD001 and AP23576) are immunosuppressor macrolides that block mTOR (mammalian target of rapamycin) functions and yield antiproliferative activity in a variety...
mTOR-targeted therapy of cancer with rapamycin derivatives (2005)
Vignot, S., Faivre, S., Aguirre, D., Raymond, E.
Rapamycin and its derivatives (CCI-779, RAD001 and AP23576) are immunosuppressor macrolides that block mTOR (mammalian target of rapamycin) functions and yield antiproliferative activity in a variety...
Monnerat, C., Henriksson, R., Le Chevalier, T., Novello, S., Berthaud, P., Faivre, S., ...
Background: PKC412 (N-benzoyl-staurosporine), an oral inhibitor of protein kinase C, is capable of cell cycle inhibition and is endowed with anti-angiogenic properties. This dose-finding phase I...
Vera, K., Djafari, L., Faivre, S., Djazouli, K., Osorio, M., ...
Background: Temozolomide has shown activity and limited toxicity in patients with primary brain tumors at doses of 150–200 mg/m2/day on days 1–5 every 4 weeks. In this study, a new alternative...
Raymond, E., Fabbro, M., Boige, V., Rixe, O., Frenay, M., Vassal, G., ...
Background: To assess the antitumour activity and safety profile of irinotecan and its pharmacokinetic interactions with anticonvulsants in patients with glioblastoma multiforme. Patients and...
NGUYEN, QD, FAIVRE, S, Bruyneel, Erik, RIVAT, C, SETO, M, ENDO, T, ...
Monnerat, C., Faivre, S., Temam, S., Bourhis, J., Raymond, E.
More than 60% of patients diagnosed with squamous cell carcinoma of the head and neck present at a locally advanced stage. Although multimodality therapy has improved locoregional control, the...
Faivre, S., Le Chevalier, T., Monnerat, C., Lokiec, F., Novello, S., Taieb, J., ...
Background: The aim of this study was to determine the toxicity profile, the recommended dose (RD) and the pharmacokinetic parameters, and to evaluate the antitumor activity of gemcitabine combined...
Delord, J.P., Raymond, E., Chaouche, M., Ruffle, P., Ducreux, M., Faivre, S., ...
Purpose: Gemcitabine and vinorelbine are active drugs with broad spectrum of activity and manageable toxicity in clinical trials. The aims of this study were to describe the toxicity, to determine...
Faivre, S., Kalla, S., Cvitkovic, E., Bourdon, O., Hauteville, D., Dourte, L. M., ...
Purpose: Compassionate-use oxaliplatin-paclitaxel was assessed for toxicity and efficacy according to clinical platinum resistance status in cisplatin-carboplatin-pretreated advanced ovarian cancer...
Serova, M, Galmarini, C M, Ghoul, A, Benhadji, K, Green, S R, Chiao, J, ...
This study assessed the antiproliferative activity of sapacitabine (CYC682, CS-682) in a panel of 10 human cancer cell lines with varying degrees of resistance or sensitivity to the commonly used...
Detection of circulating carcinoma cells by telomerase activity
Gauthier, L R, Granotier, C, Soria, J-C, Faivre, S, Boige, V, Raymond, E, ...
Telomerase has been shown to be a marker of epithelial cancer cells. We developed a method that allows the detection of circulating carcinoma cells in the blood of cancer patients. Circulating...
mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
Le Tourneau, C, Faivre, S, Serova, M, Raymond, E
The proof of principle that a drug targeting mTOR can improve survival has been obtained recently from a large randomised trial using temsirolimus as a first-line therapy in patients with advanced...